d1/3-mage-3-his fusion protein
Biologicalexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT00042783)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
immunity, active - mage3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- d1/3-mage-3-his fusion protein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00086866 | Phase 2 | May 1, 2004 | Erasmus University Rotterdam, European Organisation for Research and Treatment of Cancer, Radboud University |
| NCT00042783 | Phase 2 | Sep 1, 2002 | National Cancer Institute (NCI), Southwest Oncology Group, University of Southern California |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2004 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2002 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2002 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2002 |
6 organizations
Page 1 / 1